
Ionis Pharmaceuticals, Inc.: shareholders and insiders
Price
$27.12
November 19, 2026Market cap $4.5B
What Ploutos Investor adds for Ionis Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 19, 2025 to Nov 13, 2026, from their own Form 4 filings.
Bought on the market
$1.2M
1 person
Sold on the market
$120M
18 people
From Nov 19, 2025 to Nov 19, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan81%
- The rest19%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 19, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·bought $1.2M by 1 person·sold $113M by 16 people
- 2025: no buys, sold $7.1M by 4 people
- 2026: bought $1.2M by 1 person, sold $113M by 16 people
- Nov 10, 2026Michael R HaydenDirectorKind
- Oct 16, 2026Shannon L. DeversEVP, Chief Human Resources OfcKind
- Oct 16, 2026Eric SwayzeEVP ResearchKind
- Oct 15, 2026Shannon L. DeversEVP, Chief Human Resources OfcKind
- Oct 15, 2026Eric SwayzeEVP ResearchKind
- Aug 31, 2026C Frank BennettEVP, Chief Scientific OfficerKind
- Aug 31, 2026Patrick R. O'neilEVP CLO & General CounselKind
- Aug 31, 2026Brett P MoniaChief Executive OfficerKind
- Aug 31, 2026Brian BirchlerEVP, Corp and Development OpsKind
- Jul 31, 2026Michael R HaydenDirectorKind
- Jul 30, 2026Michael R HaydenDirectorKind
- Jul 15, 2026Joan E HermanDirectorKind
- Jul 15, 2026Spencer R BerthelsenDirectorKind
- Jul 7, 2026C Frank BennettEVP, Chief Scientific OfficerKind10b5-1
- Jul 7, 2026C Frank BennettEVP, Chief Scientific OfficerKind10b5-1
- Jul 7, 2026C Frank BennettEVP, Chief Scientific OfficerKind10b5-1
- Jul 7, 2026Allene M. DiazDirectorKind10b5-1
- Jul 7, 2026Allene M. DiazDirectorKind10b5-1
- Jul 7, 2026Holly B. KordasiewiczEVP, Chief Development OfficerKind10b5-1
- Jul 1, 2026Joseph Klein IiiDirectorKind10b5-1
- Jul 1, 2026Joseph Klein IiiDirectorKind10b5-1
- Jul 1, 2026Joseph Klein IiiDirectorKind10b5-1
- Jun 26, 2026Joseph BaroldiEVP, Chief Business OfficerKind10b5-1
- Jun 26, 2026Joseph BaroldiEVP, Chief Business OfficerKind10b5-1
- Jun 26, 2026Joseph BaroldiEVP, Chief Business OfficerKind10b5-1
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 10, 2026 | Michael R HaydenDirector | 5,000 | $29.64 | $148.2K | Form 4 | |
| Oct 16, 2026 | Shannon L. DeversEVP, Chief Human Resources Ofc | 1,357 | $43.54 | $59.1K | Form 4 | |
| Oct 16, 2026 | Eric SwayzeEVP Research | 53 | $43.54 | $2.3K | Form 4 | |
| Oct 15, 2026 | Shannon L. DeversEVP, Chief Human Resources Ofc | 2,820 | – | – | Form 4 | |
| Oct 15, 2026 | Eric SwayzeEVP Research | 125 | – | – | Form 4 | |
| Aug 31, 2026 | C Frank BennettEVP, Chief Scientific Officer | 110 | $51.31 | $5.6K | Form 4 | |
| Aug 31, 2026 | Patrick R. O'neilEVP CLO & General Counsel | 63 | $51.31 | $3.2K | Form 4 | |
| Aug 31, 2026 | Brett P MoniaChief Executive Officer | 98 | $51.31 | $5.0K | Form 4 | |
| Aug 31, 2026 | Brian BirchlerEVP, Corp and Development Ops | 58 | $51.31 | $3.0K | Form 4 | |
| Jul 31, 2026 | Michael R HaydenDirector | 5,000 | $51.60 | $258.0K | Form 4 | |
| Jul 30, 2026 | Michael R HaydenDirector | 15.0K | $53.38 | $800.7K | Form 4 | |
| Jul 15, 2026 | Joan E HermanDirector | 5,220 | – | – | Form 4 | |
| Jul 15, 2026 | Spencer R BerthelsenDirector | 5,220 | – | – | Form 4 | |
| Jul 7, 2026 | C Frank BennettEVP, Chief Scientific Officer | 10b5-1 | 5,536 | $83.58 | $462.7K | Form 4 |
| Jul 7, 2026 | C Frank BennettEVP, Chief Scientific Officer | 10b5-1 | 15.0K | – | – | Form 4 |
| Jul 7, 2026 | C Frank BennettEVP, Chief Scientific Officer | 10b5-1 | 15.0K | $85.46 | $1.3M | Form 4 |
| Jul 7, 2026 | Allene M. DiazDirector | 10b5-1 | 10.1K | $47.11 | $476.3K | Form 4 |
| Jul 7, 2026 | Allene M. DiazDirector | 10b5-1 | 10.1K | $85.42 | $863.6K | Form 4 |
| Jul 7, 2026 | Holly B. KordasiewiczEVP, Chief Development Officer | 10b5-1 | 362 | $84.30 | $30.5K | Form 4 |
| Jul 1, 2026 | Joseph Klein IiiDirector | 10b5-1 | 11.5K | $39.94 | $460.0K | Form 4 |
| Jul 1, 2026 | Joseph Klein IiiDirector | 10b5-1 | 99 | $79.45 | $7.9K | Form 4 |
| Jul 1, 2026 | Joseph Klein IiiDirector | 10b5-1 | 11.4K | $79.04 | $902.6K | Form 4 |
| Jun 26, 2026 | Joseph BaroldiEVP, Chief Business Officer | 10b5-1 | 3,866 | $56.78 | $219.5K | Form 4 |
| Jun 26, 2026 | Joseph BaroldiEVP, Chief Business Officer | 10b5-1 | 1,769 | $32.60 | $57.7K | Form 4 |
| Jun 26, 2026 | Joseph BaroldiEVP, Chief Business Officer | 10b5-1 | 5,635 | $80.16 | $451.7K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 3, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by IONS's officers and directors from 2006 up to November 18, 2025, 20 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 15 more, back to 2006
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Capital World InvestorsShare of class12.8%
- BlackRock, Inc.Share of class5.70%
- Vanguard Capital ManagementShare of class5.05%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Capital World Investors | 12.8% | 21.19M | May 14, 20263 filings since Feb 13, 2025 | 13G/A | |
| BlackRock, Inc. | 5.70% | 9.07M | Apr 17, 2025 | 13G/A | |
| Vanguard Capital Management | 5.05% | 8.34M | Apr 30, 2026 | 13G |
Fell to 5% or less (3)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Millennium Mgmt (Englander)In the quarter-73%
- Renaissance TechnologiesIn the quarter-37%
- Citadel Advisors (Griffin)In the quarter-75%
- D.E. ShawIn the quarter-31%
- AQR CapitalIn the quarter-23%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Millennium Mgmt (Englander) | 288.9K | -73% | $23M | 0.02% |
| Renaissance Technologies | 354.2K | -37% | $16M | 0.02% |
| Citadel Advisors (Griffin) | 236.3K | -75% | $19M | 0.01% |
| D.E. Shaw | 297.0K | -31% | $24M | 0.01% |
| AQR Capital | 22.1K | -23% | $1.7M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 12.5% of its shares outstanding were held short, -8.2% since the report before.
- Shares held short
- 20.65M
- 12.5%
- Since the report before22.51M on Sep 30, 2026
- -8.2%
- 7.7
- 2.70M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 82%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 9.70M
- Nov 15, 2023: Shares held short 9.74M
- Nov 30, 2023: Shares held short 9.70M
- Dec 15, 2023: Shares held short 8.56M
- Dec 29, 2023: Shares held short 8.24M
- Jan 12, 2024: Shares held short 8.54M
- Jan 31, 2024: Shares held short 8.45M
- Feb 15, 2024: Shares held short 9.06M
- Feb 29, 2024: Shares held short 9.11M
- Mar 15, 2024: Shares held short 9.67M
- Mar 28, 2024: Shares held short 9.52M
- Apr 15, 2024: Shares held short 9.53M
- Apr 30, 2024: Shares held short 8.75M
- May 15, 2024: Shares held short 8.63M
- May 31, 2024: Shares held short 8.60M
- Jun 14, 2024: Shares held short 8.65M
- Jun 28, 2024: Shares held short 9.52M
- Jul 15, 2024: Shares held short 9.37M
- Jul 31, 2024: Shares held short 9.46M
- Aug 15, 2024: Shares held short 9.90M
- Aug 30, 2024: Shares held short 10.16M
- Sep 13, 2024: Shares held short 10.61M
- Sep 30, 2024: Shares held short 10.53M
- Oct 15, 2024: Shares held short 9.87M
- Oct 31, 2024: Shares held short 10.74M
- Nov 15, 2024: Shares held short 11.05M
- Nov 29, 2024: Shares held short 10.45M
- Dec 13, 2024: Shares held short 10.53M
- Dec 31, 2024: Shares held short 10.90M
- Jan 15, 2025: Shares held short 10.24M
- Jan 31, 2025: Shares held short 12.12M
- Feb 14, 2025: Shares held short 12.67M
- Feb 28, 2025: Shares held short 12.85M
- Mar 14, 2025: Shares held short 12.81M
- Mar 31, 2025: Shares held short 13.34M
- Apr 15, 2025: Shares held short 14.55M
- Apr 30, 2025: Shares held short 14.63M
- May 15, 2025: Shares held short 15.27M
- May 30, 2025: Shares held short 14.84M
- Jun 13, 2025: Shares held short 14.23M
- Jun 30, 2025: Shares held short 14.14M
- Jul 15, 2025: Shares held short 12.89M
- Jul 31, 2025: Shares held short 11.58M
- Aug 15, 2025: Shares held short 10.79M
- Aug 29, 2025: Shares held short 10.50M
- Sep 15, 2025: Shares held short 11.97M
- Sep 30, 2025: Shares held short 12.28M
- Oct 15, 2025: Shares held short 13.70M
- Oct 31, 2025: Shares held short 12.66M
- Nov 14, 2025: Shares held short 14.22M
- Nov 28, 2025: Shares held short 15.63M
- Dec 15, 2025: Shares held short 16.09M
- Dec 31, 2025: Shares held short 14.89M
- Jan 15, 2026: Shares held short 13.73M
- Jan 30, 2026: Shares held short 15.54M
- Feb 13, 2026: Shares held short 15.49M
- Feb 27, 2026: Shares held short 15.32M
- Mar 13, 2026: Shares held short 13.95M
- Mar 31, 2026: Shares held short 14.33M
- Apr 15, 2026: Shares held short 13.76M
- Apr 30, 2026: Shares held short 16.28M
- May 15, 2026: Shares held short 16.09M
- May 29, 2026: Shares held short 16.99M
- Jun 15, 2026: Shares held short 17.76M
- Jun 30, 2026: Shares held short 17.43M
- Jul 15, 2026: Shares held short 20.04M
- Jul 31, 2026: Shares held short 21.47M
- Aug 14, 2026: Shares held short 20.91M
- Aug 31, 2026: Shares held short 20.92M
- Sep 15, 2026: Shares held short 20.89M
- Sep 30, 2026: Shares held short 22.51M
- Oct 15, 2026: Shares held short 20.65M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading35.1% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 35.1% of the shares in the reported trades were short sales, against 40.9% in the 14 before.
- Last 14 sessionsOct 30, 2026 – Nov 18, 2026
- 35.1%
- The 14 beforeOct 12, 2026 – Oct 29, 2026
- 40.9%
- Change
- -5.8 pts
- Short sales a dayon average, of 2.32M shares
- 814.6K
- More than atof 3,656 US-listed companies, same days
- 11%
- Median of alleight in ten from 34.4% to 63.7%
- 50.3%
- Short sales
- Oct 12, 2026: Short sales 36.4%
- Oct 13, 2026: Short sales 36.9%
- Oct 14, 2026: Short sales 56.5%
- Oct 15, 2026: Short sales 41.6%
- Oct 16, 2026: Short sales 41.3%
- Oct 19, 2026: Short sales 51%
- Oct 20, 2026: Short sales 49.3%
- Oct 21, 2026: Short sales 48.4%
- Oct 22, 2026: Short sales 30.9%
- Oct 23, 2026: Short sales 39.7%
- Oct 26, 2026: Short sales 29.2%
- Oct 27, 2026: Short sales 46.1%
- Oct 28, 2026: Short sales 40.1%
- Oct 29, 2026: Short sales 49.4%
- Oct 30, 2026: Short sales 30.5%
- Nov 2, 2026: Short sales 32.6%
- Nov 3, 2026: Short sales 48.5%
- Nov 4, 2026: Short sales 45.8%
- Nov 5, 2026: Short sales 31.3%
- Nov 6, 2026: Short sales 34.7%
- Nov 9, 2026: Short sales 26.2%
- Nov 10, 2026: Short sales 41.3%
- Nov 11, 2026: Short sales 26.3%
- Nov 12, 2026: Short sales 35.4%
- Nov 13, 2026: Short sales 32%
- Nov 16, 2026: Short sales 48.8%
- Nov 17, 2026: Short sales 52.1%
- Nov 18, 2026: Short sales 49.6%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Brett P MoniaChief Executive OfficerDirectly242.8K
- Spencer R BerthelsenDirectorDirectly161.3K
- Brian BirchlerEVP, Corp and Development OpsDirectly102.9K
- Elizabeth L HougenEVP, Finance & CFODirectly82.7K
- Michael R HaydenDirectorDirectly57.3K
- Eugene SchneiderEVP, Chf Clinical Develop OfcrDirectly77.1K
- C Frank BennettEVP, Chief Scientific OfficerDirectly60.1K
- Richard S GearyEVP, Chief Development OfficerDirectly59.7K
- Patrick R. O'neilEVP CLO & General CounselDirectly59.2K
- Joseph LoscalzoDirectorDirectly54.1K
- B Lynne ParshallDirectorDirectly51.9K
- Joan E HermanDirectorDirectly51.3K
- Joseph BaroldiEVP, Chief Business OfficerDirectly44.9K
- Joseph H WenderDirectorDirectly–
- Onaiza Cadoret-ManierEVP,Chf GL Pdt Str & Oper OfcDirectly35.8K
- Kyle JenneEVP, Chf GL Pdt Str OfcrDirectly23.7K
- Eric SwayzeEVP ResearchDirectly21.8K
- Holly B. KordasiewiczEVP, Chief Development OfficerDirectly22.1K
- Shannon L. DeversEVP, Chief Human Resources OfcDirectly17.8K
- Joseph Klein IiiDirectorDirectly11.0K
- Allene M. DiazDirectorDirectly3,811
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Brett P MoniaChief Executive Officer | 242.8K | – | Aug 31, 2026 | Form 4 |
| Spencer R BerthelsenDirector | 161.3K | – | Jul 15, 2026 | Form 4 |
| Brian BirchlerEVP, Corp and Development Ops | 102.9K | – | Aug 31, 2026 | Form 4 |
| Elizabeth L HougenEVP, Finance & CFO | 82.7K | – | Mar 17, 2026 | Form 4 |
| Michael R HaydenDirector | 57.3K | 24.0K | Nov 10, 2026 | Form 4 |
| Eugene SchneiderEVP, Chf Clinical Develop Ofcr | 77.1K | – | Jun 26, 2026 | Form 4 |
| C Frank BennettEVP, Chief Scientific Officer | 60.1K | – | Aug 31, 2026 | Form 4 |
| Richard S GearyEVP, Chief Development Officer | 59.7K | – | Nov 6, 2025 | Form 4 |
| Patrick R. O'neilEVP CLO & General Counsel | 59.2K | – | Aug 31, 2026 | Form 4 |
| Joseph LoscalzoDirector | 54.1K | – | May 4, 2026 | Form 4 |
| B Lynne ParshallDirector | 51.9K | – | Apr 15, 2026 | Form 4 |
| Joan E HermanDirector | 51.3K | – | Jul 15, 2026 | Form 4 |
| Joseph BaroldiEVP, Chief Business Officer | 44.9K | 4,669 | Jun 26, 2026 | Form 4 |
| Joseph H WenderDirector | – | 36.0K | Dec 1, 2025 | Form 4 |
| Onaiza Cadoret-ManierEVP,Chf GL Pdt Str & Oper Ofc | 35.8K | – | Feb 2, 2024 | Form 4 |
| Kyle JenneEVP, Chf GL Pdt Str Ofcr | 23.7K | – | Apr 16, 2026 | Form 4 |
| Eric SwayzeEVP Research | 21.8K | 318 | Oct 16, 2026 | Form 4 |
| Holly B. KordasiewiczEVP, Chief Development Officer | 22.1K | – | Jul 7, 2026 | Form 4 |
| Shannon L. DeversEVP, Chief Human Resources Ofc | 17.8K | – | Oct 16, 2026 | Form 4 |
| Joseph Klein IiiDirector | 11.0K | – | Jul 1, 2026 | Form 4 |
| Allene M. DiazDirector | 3,811 | – | Jul 7, 2026 | Form 4 |
A lower bound: it counts only the 21 officers and directors with a market trade since Nov 20, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- ARKGARK Genomic Revolution ETFWeight in the fund1.77%
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund1.00%
- IBBiShares Biotechnology ETFWeight in the fund1.00%
- LABUDirexion Daily S&P Biotech Bull 3X SharesWeight in the fund0.48%
- VBKVanguard Small-Cap Growth Index FundWeight in the fund0.35%
- IWPiShares Russell Mid-Cap Growth ETFWeight in the fund0.34%
- CGGRCapital Group Growth ETFWeight in the fund0.32%
- SCHASchwab U.S. Small-Cap ETFWeight in the fund0.21%
- SCHMSchwab U.S. Mid-Cap ETFWeight in the fund0.19%
- VXFVanguard Extended Market Index FundWeight in the fund0.15%
31 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 437
- Q4 2025: Managers 495
- Q1 2026: Managers 499
- Q2 2026: Managers 513
Institutional investors by quarter
The fund managers holding IONS, quarter by quarter, from Q4 2015 to Q2 2025, 39 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 513 managers held 180M shares, worth $14.3B. During the quarter 66 opened a position, 52 closed one, 196 added and 160 trimmed.
The largest holders, Q2 2026
- FMRIn the quarter+0.3%
- Capital World InvestorsIn the quarter+2.3%
- BlackRockIn the quarter+2.5%
- Vanguard Portfolio ManagementIn the quarter+0.6%
- Wellington Management GroupIn the quarter+20%
- Vanguard Capital ManagementIn the quarter+1.3%
- Two Sigma InvestmentsIn the quarter+6.7%
- Royal Bank of CanadaIn the quarter+63%
- State StreetIn the quarter+8.5%
- T. Rowe Price Investment ManagementIn the quarter-36%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| FMR | 24.63M | +0.3% | $2.0B |
| Capital World Investors | 21.67M | +2.3% | $1.7B |
| BlackRock | 10.70M | +2.5% | $849M |
| Vanguard Portfolio Management | 7.86M | +0.6% | $623M |
| Wellington Management Group | 7.65M | +20% | $607M |
| Vanguard Capital Management | 7.21M | +1.3% | $572M |
| Two Sigma Investments | 6.25M | +6.7% | $496M |
| Royal Bank of Canada | 6.18M | +63% | $490M |
| State Street | 4.33M | +8.5% | $344M |
| T. Rowe Price Investment Management | 3.96M | -36% | $314M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Ionis Pharmaceuticals's filings show?
Who buys and sells is one part of Ionis Pharmaceuticals's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have IONS's insiders bought or sold?
From Jun 3, 2026 to Nov 13, 2026 Ionis Pharmaceuticals's insiders bought $1.2M and sold $20M of shares on the market. 100% of the sales were under set 10b5-1 plans.
Which well-known managers hold IONS?
5 of the managers we track held the shares on Sep 30, 2026. The largest position was D.E. Shaw's, worth $24M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.